By Robb M. Stewart
BeiGene Ltd.'s trial of a potential treatment for patients in hospital with respiratory symptoms of Covid-19 failed to meet the two primary efficacy endpoints of the study.
The biotechnology company said its Phase 2 trial evaluating zanubrutinib in patients hospitalized with respiratory symptoms of Covid-19 and requiring supplemental oxygen without mechanical ventilation, didn't meet the co-primary efficacy endpoints of respiratory failure-free survival or reduction in days on oxygen as compared with a placebo.
There were no new or additional safety signals for zanubrutinib identified in the trial, it added.
The U.S. trial enrolled 67 patients with Covid-19 disease who either required supplemental oxygen or mechanical ventilation. It was designed to assess quickly whether treatment with zanubrutinib could help hospitalized patients with Covid-19-related pulmonary distress. Zanubrutinib is a small molecule inhibitor of Bruton's tyrosine kinase discovered by BeiGene scientists.
Following the update on the trial, BeiGene's American depositary receipts were down 0.9% in premarket trading after ending Wednesday at $321.60, a gain of almost 25% so far in 2021.
Write to Robb M. Stewart at firstname.lastname@example.org
(END) Dow Jones Newswires